Geneva Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.98M | Buy |
13,065
+268
| +2% | +$40.7K | 0.03% | 113 |
|
|
2025
Q1 | $1.93M | Buy |
12,797
+7
| +0.1% | +$1.05K | 0.04% | 115 |
|
|
2024
Q4 | $2.36M | Sell |
12,790
-2,026
| -14% | -$374K | 0.04% | 116 |
|
|
2024
Q3 | $2.92M | Sell |
14,816
-418
| -3% | -$82.3K | 0.05% | 114 |
|
|
2024
Q2 | $3.15M | Sell |
15,234
-1,284
| -8% | -$265K | 0.06% | 112 |
|
|
2024
Q1 | $4.48M | Buy |
16,518
+244
| +1% | +$66.1K | 0.08% | 104 |
|
|
2023
Q4 | $3.85M | Sell |
16,274
-1,474
| -8% | -$348K | 0.07% | 103 |
|
|
2023
Q3 | $3.48M | Sell |
17,748
-641
| -3% | -$126K | 0.07% | 108 |
|
|
2023
Q2 | $3.87M | Sell |
18,389
-1,044
| -5% | -$219K | 0.08% | 103 |
|
|
2023
Q1 | $3.92M | Sell |
19,433
-617
| -3% | -$125K | 0.08% | 104 |
|
|
2022
Q4 | $4.37M | Buy |
20,050
+63
| +0.3% | +$13.7K | 0.1% | 102 |
|
|
2022
Q3 | $3.93M | Sell |
19,987
-2,189
| -10% | -$431K | 0.09% | 108 |
|
|
2022
Q2 | $4.75M | Sell |
22,176
-306
| -1% | -$65.5K | 0.11% | 103 |
|
|
2022
Q1 | $6.38M | Buy |
+22,482
| New | +$6.38M | 0.12% | 106 |
|